MiMedx Group, Inc Common Stock MDXG
i
Market datapartial · fetched 2026-11-03T18:59:46.130Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2027-03-19
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T18:59:35.493986315Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-03T18:59:44.044804+00:00
MiMedx Group, Inc Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | 5.67 | 116.7% | 89.6% | |||
| 40Δ | 4.80 | 103.0% | 63.8% | |||
| 45Δ | 4.51 | 98.3% | 56.7% | |||
| 50Δ | 4.23 | 93.7% | 49.6% | |||
| 55Δ | 3.94 | 89.0% | 42.5% | |||
| 60Δ | 3.65 | 84.4% | 35.4% | |||
| 65Δ | 3.37 | 79.7% | 28.3% | |||
| 70Δ | 3.08 | 75.1% | 21.2% | |||
| 75Δ | 2.79 | 70.4% | 14.1% | |||
| 80Δ | 2.51 | 65.8% | 6.9% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 5.67
- IV
- 116.7%
- B/E move
- 89.6%
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 4.80
- IV
- 103.0%
- B/E move
- 63.8%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 4.51
- IV
- 98.3%
- B/E move
- 56.7%
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 4.23
- IV
- 93.7%
- B/E move
- 49.6%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 3.94
- IV
- 89.0%
- B/E move
- 42.5%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 3.65
- IV
- 84.4%
- B/E move
- 35.4%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 3.37
- IV
- 79.7%
- B/E move
- 28.3%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 3.08
- IV
- 75.1%
- B/E move
- 21.2%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 2.79
- IV
- 70.4%
- B/E move
- 14.1%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 2.51
- IV
- 65.8%
- B/E move
- 6.9%
- Pseudo strike
- IV
- B/E move
Options history
No recorded observations
Biotechnology
MESO
Mesoblast Limited, a biopharmaceutical company, develops and markets allogeneic cellular drugs. The company is headquartered in Melbourne, Australia.
More →MGNX
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. The company is headquartered in Rockville,…
More →MGTX
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focused on developing treatments for patients living with serious illnesses. The company is headquartered in New…
More →MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies for debilitating liver…
More →MIST
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular drugs. The company is headquartered in Montral,…
More →MLTX
Description unavailable
More →